FROM 01 December Eylea
(aflibercept) will be available on the
Pharmaceutical Benefits Scheme
for the treatment of neovascular
(wet) Age-related Macular
Degeneration.
Eylea is a novel recombinant
fusion protein which works by
trapping excess vascular
endothelial growth factor (VEGF) in
the eye and has a higher binding
affinity for VEGF than natural
receptors have.
Trapping excess VEGF limits the
growth of abnormal blood vessels
and hence reduces leakage.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Oct 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Oct 12
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.